No. 25

Explainable artificial intelligence increases the accuracy and endurance of dermatologists in melanoma diagnosis

Bastian Schilling, wearing eye-tracking glasses, sits smiling at his laptop, which displays an image of the skin.
Bastian Schilling, Director at the Dermatology Clinic of Frankfurt University, was one of the dermatologists participating in the current study.

Scientists at the German Cancer Research Center (DKFZ) have shown in an international eye-tracking study that dermatologists not only improve their diagnostic accuracy by using explainable artificial intelligence, but also show significantly less fatigue when assessing challenging cases. The researchers were able to demonstrate this by measuring a reduction in cognitive stress indicators.

In a two-phase study, 76 dermatologists each assessed 16 images (melanomas and benign moles, known as nevi) taken with a dermatoscope, an illuminated magnifying glass, first using standard AI and then with an explainable AI solution. Explainable AI, or XAI for short, combines AI predictions with textual and image-based explanations based on established dermatoscopic features. Eye-tracking measurements were used to record how long and how intensively the participants looked at certain image regions and explanations.

Eye tracking as an objectification method

Analysis of gaze patterns showed that difficult cases were associated with an increased number of fixations – an objective indicator of cognitive effort. In the XAI phase, this effort decreased in challenging cases compared to standard AI, indicating a relieving effect of the explanations provided.

“Our results show that explainable AI not only increases diagnostic confidence, but can also support endurance in difficult cases in clinical practice,” explains Titus J. Brinker, senior author of the current study. “Especially with a high caseload and complex lesions, explainable artificial intelligence can help prevent fatigue and thus minimize potential sources of error.”

Follow-up studies are planned to investigate the long-term impact on workload and diagnostic quality in real-world clinical settings.

 

Chanda, T., Haggenmueller, S., Bucher, TC. et al. Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking study.
Nature Communications, 2025, https://doi.org/10.1038/s41467-025-59532-5

Get in touch with us

Employee image

Press Contact

About DKFZ

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

Form

Form data is loaded ...